^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Nat Rev Neurol
    Title:

    Management of brain metastases according to molecular subtypes

    Published date:
    09/01/2020
    Excerpt:
    Several generations of EGFR and ALK inhibitors have shown activity on brain metastases from EGFR and ALK mutant non-small-cell lung cancer.
    DOI:
    10.1038/s41582-020-0391-x